Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$324.1m

Revance Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RVNC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24SellUS$16,296David HollanderIndividual3,908US$4.17
16 Apr 24SellUS$9,096Erica JordanIndividual2,392US$3.80
18 Mar 24SellUS$40,971Dwight MoxieIndividual8,125US$5.04
18 Mar 24SellUS$46,446Dustin SjutsIndividual9,211US$5.04
18 Mar 24SellUS$47,204Tobin SchilkeIndividual9,361US$5.04
06 Mar 24BuyUS$209,400Mark FoleyIndividual30,000US$6.98

Insider Trading Volume

Insider Buying: RVNC insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of RVNC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,906,8651.82%
Private Companies6,550,8006.24%
General Public11,526,19411%
Institutions84,918,52981%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.

Top Shareholders

Top 25 shareholders own 66.83% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.32%
BlackRock, Inc.
8,727,584US$27.0m1.89%no data
6.24%
Teoxane S.A.
6,550,800US$20.2m0%no data
5.47%
The Vanguard Group, Inc.
5,733,699US$17.7m-4.35%no data
4.52%
Franklin Resources, Inc.
4,744,940US$14.7m-24.2%0.01%
4%
Fidelity International Ltd
4,192,933US$13.0m0%0.01%
3.97%
Alpine Associates Management Inc.
4,162,861US$12.9m0%0.83%
3.11%
AllianceBernstein L.P.
3,260,471US$10.1m2,600%no data
2.38%
Magnetar Capital Partners, LP
2,500,171US$7.7m0%0.23%
2.38%
Tang Capital Management, LLC
2,500,000US$7.7m525%0.58%
2.32%
State Street Global Advisors, Inc.
2,433,963US$7.5m6.58%no data
2.27%
Water Island Capital, LLC
2,381,196US$7.4m0%1.11%
2.2%
Squarepoint OPS LLC
2,309,662US$7.1m0%0.02%
2.18%
Geode Capital Management, LLC
2,289,654US$7.1m-0.36%no data
2.14%
LMR Partners LLP
2,244,400US$6.9m0%0.2%
1.84%
D. E. Shaw & Co., L.P.
1,932,205US$6.0m1,690%0.01%
1.8%
Qube Research & Technologies Ltd
1,891,261US$5.8m0%0.01%
1.59%
Kryger Capital Limited
1,667,359US$5.2m0%0.65%
1.57%
Beryl Capital Management LLC
1,642,448US$5.1m0%1.07%
1.54%
Palo Alto Investors LP
1,611,787US$5.0m-69.3%0.7%
1.44%
AQR Capital Management, LLC
1,511,316US$4.7m652%0.01%
1.29%
Madison Avenue Partners, LP
1,353,321US$4.2m0%0.31%
1.12%
HSBC Global Asset Management (UK) Limited
1,170,438US$3.6m7,730%no data
1.08%
GAMCO Investors, Inc.
1,133,650US$3.5m0%0.01%
1.06%
Mark Foley
1,106,848US$3.4m0%no data
1%
Adage Capital Management, L.P.
1,050,000US$3.2m0%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Revance Therapeutics, Inc. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Balaji PrasadBarclays
Balaji PrasadBarclays